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Abstract 
Heart failure causes significant morbidity and mortality, with recognised underutilisation rates of 
guideline based therapies. Our aim was to review current evidence for heart failure treatments and 
derive a mnemonic summarising best practice which might assist physicians in patient care. 
Treatments were identified for review from multinational society guidelines and recent randomised 
trials, with a primary aim of examining their effects in systolic heart failure patients on mortality, 
hospitalisation rates and symptoms. Secondary aims were to consider other clinical benefits. 
MEDLINE and EMBASE were searched using a structured keyword strategy and the retrieved articles 
were evaluated methodically to produce an optimised reference list for each treatment. We devised 
the mnemonic BANDAID2, standing for Beta-blocker, ACE inhibitor/ARB, Hydralazine-Isosorbide 
DiNitrate (or potentially Neprilysin inhibitor), Diuretics, Aldosterone antagonist, Ivabradine, Devices 
(AICD, CRT or both) and Digoxin as a representation of treatments with strong evidence for their use 
in systolic heart failure. Treatment with omega-3 fatty acids, statins or anti-thrombotic therapies has 
limited benefits in a general heart failure population. Adoption of this mnemonic for current 
evidence based treatments for heart failure may help improve prescribing rates and patient 
outcomes in this debilitating, high mortality condition. 
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Introduction 
Heart failure is a chronic disease with significant morbidity and mortality. In Australia, its prevalence 
rises from 1% at age 50 years  to over 50% at 85 years or older and it is one of the most common 
reasons for physician consultation and hospital admission in people over 70.1 Between 20-30% of 
patients with mild-moderate heart failure and 50% of patients with severe heart failure die within a 
year.2 Several evidence based treatments exist that provide both symptomatic and mortality 
benefits. However, treatment rates are substantially lower than expected rates of intolerance or 
contraindication – for example, observational data on patient discharges from a regional New South 
Wales hospital found ACE inhibitors or ARBs were prescribed in only 65% of heart failure patients.3 
In time pressured environments of patient care, simple strategies aimed at improving guideline 
based prescribing rates are well placed to improve outcomes. Mnemonics are frequently adopted in 
medical education to recall lists of causes and treatments. The aim of this review was to 
systematically examine the current evidence base for chronic heart failure treatments in order to 
derive a contemporary mnemonic for best practice therapies to assist clinicians in their patient care. 
Methods 
The primary search aim was to identify treatments that provide mortality, hospitalisation or 
symptomatic benefits, in comparison to placebo, in chronic systolic heart failure patients. A starting 
list of treatments (pharmacological and device-based) was obtained after reviewing the most recent 
AHA/ACCF Guidelines (2013),4 ESC Chronic Heart Failure Guidelines (2012)5 and Australian National 
Heart Failure Guidelines (2011).1 For the purpose of this review, highly specialised therapies such as 
ventricular assist devices and cardiac transplantation were not included. Both MEDLINE and EMBASE 
databases were used to obtain reference lists based on a structured search strategy (supplementary 
appendix, p1). Titles and abstracts were screened to exclude duplicates and unsuitable articles 
producing a list of studies in which the full text was assessed using PRISMA guidelines to further 
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determine suitability.6 Meta-analyses of individual patient data from randomised trials were 
identified as representative of the highest level of evidence. If these were not available, meta-
analyses of published trial data were used, providing the baseline trial populations were considered 
equivalent. If meta-analyses were not available or suitable, individual randomised controlled trials 
were sought. Additional factors considered in article selection included the date of publication, the 
potential for publication bias in meta-analyses, and randomised controlled trial evidence published 
subsequent to previous meta-analyses. Two co-authors independently performed a literature search 
and results were jointly reviewed to derive an optimised reference list for each medication. 
Results 
The search strategy was performed for beta-blockers, angiotensin converting enzyme (ACE) 
inhibitors, angiotensin receptor blockers (ARBs), neprilysin inhibitors, hydralazine + isosorbide 
mononitrate (H-ISDN), diuretics, aldosterone antagonists, ivabradine, implantable cardioverter 
defibrillators (ICDs), cardiac resynchronisation therapy (CRT), digoxin, omega-3 fatty acids, 
antithrombotic therapies and HMG-CoA reductase inhibitors (statins). The literature search 
identified 2527 primary articles after removing duplicates. Of these, 609 manuscripts were selected 
for full-text review. (Figure 1) 
Beta-blockers 
Long acting beta-blockers (carvedilol, metoprolol succinate, bisoprolol, bucindolol, nebivolol and 
atenolol) have a large body of evidence supporting their efficacy in symptomatic heart failure with 
reduced ejection fraction (≤40%). A meta-analysis of 22 trials involving over 10,000 patients found 
that beta-blockers (prescribed in addition to ACE inhibitors) reduced the odds of all-cause mortality 
by 35% (OR 0.65, 95% CI [0.53-0.80]) and hospitalisation for heart failure by 36%, compared to 
placebo.7 While individual randomised controlled trials for bucindolol, nebivolol and atenolol have 
not shown independently significant mortality reductions, a network meta-analysis including these 
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trials concluded there is no significant difference between individual beta blockers, and that the 
benefits of beta blockers in heart failure are a class effect.8 Recently, a large meta-analysis of 
individual patient data suggested heart failure patients with atrial fibrillation, compared to those in 
sinus rhythm, may not benefit from mortality reductions with beta-blockers (interaction p<0.0001).9 
Although a highly significant interaction, this has not been a prespecified outcome finding of any 
randomised controlled trial. Several baseline population differences exist between heart failure 
patients in sinus rhythm and atrial fibrillation which may have influenced these findings.  
Beta-blockers are safest in symptomatic heart failure when initiated at the lowest possible dose and 
doubled at regular intervals of two weeks, helping to avoid common adverse effects such as 
worsening heart failure, hypotension and bradycardia.10 To manage symptomatic hypotension at low 
doses, the ESC Chronic Heart Failure Guidelines 2012 recommend switching between beta-blockers 
before reducing the dose of other hypotensive agents such as ACE inhibitors, diuretics or nitrates.5 
Although patients with chronic airway disease were excluded in most clinical trials, cardioselective 
beta-blockers have demonstrated to be generally safe in the short term, although long term trials 
are lacking.11  
Angiotensin Converting Enzyme Inhibitors 
A systematic review of randomised controlled trials in moderate-severe heart failure patients (EF 
≤35% or ≤40%) showed ACE inhibitors reduce the odds of all-cause mortality by 23% (OR 0.77, 95% 
CI [0.67-0.88] P<0.001) and readmissions for heart failure by 35%, compared to placebo.12 Mortality 
reductions from ongoing therapy have been demonstrated out to twelve years of follow up.13 The 
risk of developing atrial fibrillation also appears reduced by ACE inhibitors (or ARBs) in heart 
failure.14 In patients with ischaemic heart failure ACE inhibitors also reduce the risk of recurrent 
myocardial infarction, compared to placebo, by 21%.15 Overall treatment effects of ACE inhibitors 
have been shown to be consistent regardless of gender, race and diabetic status,16 and are additive 
to beta blocker therapy. 
4 
 
Adverse effects associated with ACE inhibitors include cough, hypotension, hyperkalaemia and renal 
dysfunction.15 However, even in most patients with advanced chronic kidney disease they can be 
used effectively. In the minority of situations where adverse effects have required treatment 
cessation, such side effects are reversible.  
Angiotensin Receptor Blockers  
 A Cochrane review of 17,900 pooled trial participants with EF≤40% showed that ARBs, compared to 
placebo, reduced the risk of all-cause mortality by 13% (RR 0.87, 95% CI [0.76-1.00] P=0.05) and 
readmissions for heart failure by 29%.17 Compared to ACE inhibitors, ARBs provide similar benefits in 
terms of reducing the risk of all-cause mortality, total hospitalisations and, in ischaemic heart failure, 
recurrent myocardial infarction (MI), and have similar side effects, except cough.17 When used in 
combination with ACE inhibitors, ARBs further reduce the risk of readmission for heart failure by 
19%, but there is no additional reduction in the risk of all-cause mortality or total hospitalisations.17 
Moreover, compared to ACE inhibitor therapy alone, combination therapy is associated with a much 
greater risk of renal dysfunction (91% higher risk), hyperkalaemia (95%) and symptomatic 
hypotension (57%).18  
Hydralazine and Isosorbide Dinitrate (H-ISDN) 
H-ISDN have been trialed in combination in heart failure based on their separate and theoretically 
complementary mechanisms of action - ISDN reduces preload and hydralazine reduces afterload.19 
Together they have been shown to provide mortality benefits and symptomatic relief in systolic 
heart failure. V-HeFT I demonstrated a 25% lower risk of all-cause mortality and improved exercise 
capacity with H-ISDN compared to placebo in heart failure patients already receiving digoxin and 
diuretics.20 However V-HeFT II, comparing H-ISDN to enalapril, showed a significantly lower all-cause 
mortality rate with enalapril at 2 years (ARR 5.4%, p=0.02), with a similar but non-significant result at 
the 2.5 year trial end (ARR 5.4%, p=0.08).21  
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Some preliminary evidence has suggested African Americans may derive greater benefits from H-
ISDN than ACE inhibitors, whilst in Caucasians the reverse appears true, but no statistically 
significant heterogeneity between race and treatment effect for either of these medications has 
been convincingly demonstrated.22 Headaches and dizziness (~30%) are common side effects of this 
therapy.20, 21 The evidence for using H-ISDN with an ACE inhibitor (or ARB) is sparse (with the 
exception of use in African Americans), but when the latter are contraindicated, H-ISDN appears a 
reasonable, possibly less efficacious alternative. 
Diuretics  
Although diuretics have used for decades to treat volume overload in heart failure, their efficacy is 
supported by mainly small and dated randomised controlled trials. A Cochrane review comprised of 
both randomised controlled trials and withdrawal studies found that diuretics reduced the odds of 
all-cause mortality by 76% (OR 0.24, 95% CI (0.07-0.83), p=0.02) and readmission for heart failure by 
93%, while improving exercise capacity compared to placebo.23 This meta-analysis excluded trials of 
aldosterone antagonists on the basis that they are not “conventional diuretics”, and hence results 
reflect trials of mainly loop and hydrochlorothiazide diuretics. Adverse effects of diuretics can 
include electrolyte and renal function abnormalities.   
Aldosterone antagonists 
The addition of an aldosterone antagonist (eplerenone or spironolactone) to ACE inhibitor, beta-
blocker and other diuretic therapy is a more recently established core component of the standard 
therapeutic regimen in severe heart failure (EF≤35%). A meta-analysis of 8 randomised controlled 
trials showed that compared to placebo, aldosterone antagonists reduced the odds of all-cause 
mortality by 26% (OR 0.74, 95% CI [0.63-0.86] P<0.001), driven mostly by reductions in sudden 
cardiac deaths (23%).24 Another meta-analysis showed significant reductions in the odds of all-cause 
hospitalisation (27%) and improvements in NYHA functional class and ejection fraction (~3%) with 
aldosterone blockade compared to placebo.25  
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Hyperkalaemia and renal impairment are well known risks for these medications and as a result 
patients with hyperkalaemia (serum K≥5.0mmol/L) or renal impairment (eGFR<30mL/min/1.73m2 or 
serum creatinine >221 μmol/L) were excluded from the large randomised trials. Endocrine side 
effects from spironolactone include gynaecomastia, decreased libido and, in women, menstrual 
irregularities. These can be avoided with eplerenone due to greater drug target specificity, which is 
currently PBS subsidised in Australia for early ischaemic heart failure but not for other aetiologies.   
Ivabradine 
Ivabradine reduces heart rate by specific inhibition of funny channels (If) in the sinus node. A meta-
analysis of individual patient data from two large randomised controlled trials in ~12000 patients 
with a reduced ejection fraction (≤35% or ≤40%) and heart rate ≥70bpm, found ivabradine did not 
reduce the overall risk of all-cause and cardiovascular mortality but did reduce readmissions for 
heart failure by 19% and the risk of MI by 23% compared to placebo.26 In a pre-specified subgroup 
with baseline heart rate ≥75bpm, the risks of both all-cause mortality (HR 0.89, 95% CI [0.80-1.00] 
P=0.048) and cardiovascular mortality (HR 0.88, 95% CI [0.78-1.00] P=0.049) were significantly 
reduced.26 The treatment effects of ivabradine were independent of NYHA class status and beta-
blocker doses.26 
Ivabradine is generally well-tolerated but adverse effects can include symptomatic bradycardia (4%) 
and the development of phosphenes (false sensations of seeing lights, 3%).26 These adverse effects 
rarely caused withdrawal from treatment in the randomised trials and are reversible when the drug 
is withdrawn. 
Current ESC Chronic Heart Failure Guidelines (2012) and Australian Heart Foundation Guidelines 
(2011) recommend considering ivabradine in symptomatic heart failure patients (EF ≤35%) with 
sinus rhythm and HR≥70bpm,1, 5 noting that PBS authority in Australia restricts subsidies to people 
with baseline HR>77bpm, which was the subgroup in the SHIFT trial demonstrating mortality 
benefits. 
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Devices 
AICD 
Automatic Implantable Cardioverter Defibrillators (AICDs) are used for the primary prevention of 
ventricular arrhythmias and sudden cardiac death in heart failure patients. In a meta-analysis of 
randomised controlled trials of NYHA II-III patients with sinus rhythm and EF ≤35%, AICDs reduced 
the risk of all-cause mortality by 26% (RR 0.74, 95% CI [0.67-0.83], P<0.00001) compared to medical 
therapy alone.27 A mortality benefit was not seen in patients who started therapy within 40 days of 
having a myocardial infarction,28 and existing AHA/ACCF guidelines recommend implantation 
according to an ejection fraction determined more than 40 days post-MI.4 The same guidelines also 
recommend AICD implantation in NYHA I ischaemic heart failure patients with a lower ejection 
fraction (≤30%).4 There is a lack of evidence for AICDs in NYHA class IV patients which mainly reflects 
the poor prognosis and typical exclusion of such patients from these trials. The current consensus is 
that patients should have a prognosis of at least 12 months to warrant AICD insertion.5  
CRT 
Cardiac resynchronisation therapy (CRT) provides an individually optimised pacing of both ventricles 
to improve pump performance. An individual patient data meta-analysis examined randomised 
controlled trials of NYHA II-IV participants with sinus rhythm, EF≤35%, increased QRS duration 
(≥120ms) and optimal medical therapy. It found CRT, compared to control (AICD/pacemaker/optimal 
medical therapy) was associated with a reduced risk of all-cause mortality by 34% (HR 0.66, 95% CI 
[0.57-0.77]) and a reduced risk of the combined endpoint of all-cause mortality and hospitalisation 
for heart failure.29 Benefits were independent of AICD presence, aetiology of heart failure and QRS 
morphology, noting the vast majority of subjects had LBBB.  
Analyses according to QRS duration have identified greater clinical benefits with longer durations, 
starting from QRS duration ≥140ms.29 Conversely a small meta-analysis found a higher mortality risk 
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for CRT in patients with QRS<130ms compared to medical therapy (RR 1.63, 95% CI [1.07-2.47] 
P=0.023), despite echocardiographic evidence of dyssynchrony in most patients.30 
QRS morphology also appears to influence prognosis. A meta-analysis of four CRT trials (n=5356) 
found CRT significantly reduced composite clinical events in LBBB patients but had no benefits in 
non-LBBB patients.31 Long term follow up of the MADIT-CRT trial identified significant reductions in 
the risk of all-cause mortality (41%) and non-fatal heart failure events (62%) out to seven years in 
patients with LBBB, but increased risks of both outcomes with CRT in patients without LBBB.32 More 
data for outcomes in patients with non-LBBB conduction abnormalities are required to help clarify 
these findings. 
CRT and AICD share similar adverse effects including lead problems, infection and mechanical 
complications. AICDs also risk inappropriate shocks, the psychological stress from which can 
sometimes significantly impair quality of life.  
Currently, major guidelines recommend CRT for NYHA III-IV patients with EF≤35%, sinus rhythm, 
LBBB and QRS duration ≥120ms. For patients without LBBB, the AHA/ACCF Guidelines (2013) and 
ESC Chronic Heart Failure Guidelines (2012) recommend CRT at QRS duration (≥150ms). For NYHA II 
patients international guidelines differ slightly, and the notably harmful findings from long term 
MADIT-CRT follow up in non LBBB patients suggests the appropriateness of CRT may be limited to 
more symptomatic patients.32 Only AHA/ACCF Guidelines (2013) include CRT for NYHA I patients, 
suggesting consideration in patients with severe ischaemic EF impairment (≤30%), LBBB and a broad 
QRS (>150ms).   
Digoxin 
Digoxin has traditionally been used in the setting of atrial fibrillation and advanced heart failure. A 
Cochrane review showed that digoxin did not reduce all-cause and heart failure mortality but did 
reduce heart failure symptoms and readmissions for heart failure by 32% (OR 0.68, 95% CI [0.61-
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0.75], p<0.00001).33 Benefits appeared greater in patients with severely reduced ejection fraction 
(≤25%) or NYHA III-IV functional class.34 Post-hoc subgroup analyses by serum digoxin concentrations 
(SDC) found patients within the range 0.5-0.8 ng/mL had their risk of all-cause mortality reduced by 
20% (HR 0.80, 95% CI [0.68-0.94] P=0.005). Increased arrhythmic complications have been identified 
in patients with SDC concentrations ≥1.2 ng/mL.35 If used in the context of any renal impairment, 
digoxin requires very careful dose and level monitoring to prevent toxicity. 
Drugs with limited evidence 
Omega-3 fatty acids 
Evidence for fish oil supplementation in heart failure patients is limited but modestly supportive. 
One randomised controlled trial found that 1g (850-882mg of DHA and EPA in 1.5:1) of omega-3 
fatty acids per day, compared to placebo, reduced the risk of all-cause mortality by 9% (HR 0.91, 95% 
CI [0.833-0.998] P=0.041) at 2 years but did not affect rates of hospitalisation.36 A meta-analysis of 
prospective observational studies examining incident heart failure according to fish oil intake 
demonstrated a linear protective association, with a 5% lower risk per 15g of fish consumed daily.37 
Nausea is the most common side effect but typically does not prompt drug discontinuation. 
Antithrombotic therapy in sinus rhythm 
Left ventricular systolic dysfunction is associated with an increased risk of thromboembolism in 
patients with sinus rhythm but the evidence for benefit from antithrombotic therapy is not 
definitive. In a Cochrane review of trials including heart failure patients in sinus rhythm, warfarin 
non-significantly reduced the risk of all-cause mortality (OR 0.66, 95% CI [0.36-1.18] P=0.16) 
compared to placebo.38 Other larger randomised trials of heart failure have shown no difference 
between warfarin, aspirin and clopidogrel for mortality risk and reported conflicting findings 
regarding heart failure readmissions.39, 40 Warfarin has been shown in heart failure patients to 
reduce the risk of ischaemic stroke by 48% compared to aspirin39 and the risk of any stroke 
compared to either aspirin or clopidogrel.40  
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Factored against these benefits, the risk of major haemorrhage is significantly increased with 
warfarin use compared to placebo (OR 5.98, 95% CI [1.71-20.93] P=0.0052),38 aspirin (OR 2.21, 95% 
CI [1.42-3.47], p<0.001)39 or clopidogrel (RR 2.48, CI not presented, p=0.007).40   
Statins 
Statins (HMG-CoA reductase inhibitors) are widely used to treat ischaemic heart disease but there is 
limited evidence for their use in all heart failure patients. A meta-analysis of 10 randomised 
controlled trials with symptomatic heart failure and standard baseline therapies showed no 
significant effects with statin therapy vs placebo on the risk of all-cause mortality (OR 0.89, 95% CI 
[0.72-1.10], p=0.27) or hospitalisations for heart failure, without any excess in adverse events.41 
Current evidence suggests statin prescription should not routinely be given to these patients unless 
they have other indications such as ischaemic heart or cerebrovascular disease.  
ARB and Neprilysin inhibitor combination 
LCZ696 (valsartan and sacubitril) is a promising novel combination therapy based on results from a 
large single phase III randomised controlled trial. The recently published trial included NYHA II-IV 
patients with reduced ejection fraction (≤40%) and baseline treatment with beta-blockers, diuretics, 
digoxin and aldosterone antagonists. It found that compared to ACE inhibitor therapy, LCZ696  
reduced the risk of all-cause mortality by 16% (HR 0.84; 95% CI, 0.76 to 0.93; P<0.001) and 
hospitalisation for heart failure by 21%.42 Whilst data is preliminary and continues to accrue, results 
are encouraging. 
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Discussion 
Heart failure is a condition with substantial morbidity and mortality and there is an acknowledged 
deficiency between evidence-based recommended treatments and everyday prescribing patterns. 
Mnemonics represent a simple way to assist clinicians in their treatment of patients, and in this 
manuscript we have sought to review the contemporary evidence base for systolic heart failure 
treatments to devise a mnemonic summarising these treatments. Based on this review we propose 
use of the mnemonic BANDAID2 - representing Beta-blocker, ACE inhibitor/Angiotensin Receptor 
Blocker, Nitrates-Hydralazine (or potentially Neprilysin inhibitor in the future), Diuretics, 
Aldosterone Antagonist, Ivabradine, Devices and Digoxin in approaching the treatment of systolic 
heart failure. 
There is strong evidence to support the use of beta-blockers, ACE inhibitors and ARBs in systolic 
heart failure, noting a choice of either ACE inhibitor or ARB is generally preferable to the use of both. 
Treatment with H-ISDN is effective but inferior to ACE inhibitors (and to ARBs by indirect 
comparison) in the general population. The novel combination therapy LCZ696 (valsartan and 
sacubitril (a neprilysin inhibitor)) has promising preliminary results but more research is required. 
The evidence for diuretics is limited but supports a mortality reduction and their symptomatic 
benefits in treating fluid overload are undisputed. Aldosterone antagonists significantly reduce 
mortality and hospitalisations in heart failure patients. Ivabradine reduces hospitalisations for heart 
failure in sinus rhythm patients with HR≥70bpm and, in patients with resting heart rate ≥75bpm, 
reduces both all-cause and cardiovascular mortality. However beta blockers should be used prior to 
ivabradine, when possible, on account of more definitive mortality benefits.  AICDs reduce the risk of 
sudden cardiac death in medically stabilised, NYHA II-III patients with EF≤35% in sinus rhythm, noting 
some recommendations for use in NYHA I ischaemic heart failure patients. CRT-D reduces mortality 
amongst NYHA III-IV patients with EF≤35% in sinus rhythm, with recommendations according to QRS 
morphology and duration – for LBBB ≥120ms and for non-LBBB >150ms, noting use amongst NHYA II 
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and I patients is more controversial due to evidence of harm in some non-LBBB settings. 
Recommendations for digoxin are less definitive because of a lack of clear mortality benefit despite 
reductions in hospitalisations. Most guidelines therefore recommend digoxin as the last line of 
treatment for heart failure, irrespective of rhythm.   
Importantly, most of these medications or device interventions were trialed in patients receiving 
existing standards of care of the time for heart failure. This provides reassurance that risk reductions 
from treatments should in most instances be additive when used in combination in appropriately 
selected patients. (Figure 2)  
An area not examined in this review is the critical role of heart failure outpatient services in 
providing the frequent monitoring and consultation patients with advanced heart failure require. 
Prevention of hospitalisations and associated morbidity can successfully be achieved by titrating 
medication doses, particularly diuretics, early in the course of deteriorating symptoms or increasing 
weight. Similarly, advances in remote ICD/PPM monitoring allow expedited responses to rhythm, 
rate and other physiological changes which can effectively prevent patient deteriorations. Beyond 
achieving standards in pharmacological and device therapeutics, the importance of frequent 
monitoring and review in heart failure patients cannot be overstated.  
Conclusion 
It is essential that patients are prescribed optimal evidence-based therapies in both hospital and 
community settings, as effective management of heart failure can substantially reduce morbidity 
and mortality. Consideration of BANDAID2, representing a current evidence based treatment 
mnemonic for patients with systolic heart failure, could improve prescribing rates and therefore 
patient outcomes in this complex chronic disease. 
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Figure Legends 
Figure 1. PRISMA flow diagram for search strategy results. 
Figure 2. Effects on total mortality in patients with systolic heart failure, by treatment allocation 
compared to placebo.  
OR=odd ratio; HR=hazard ratio; RR=risk ratio 
*Combination pharmacotherapy represents a broad estimate of the potential clinical benefits from 
combining treatments marked with an asterisk. The effect of diuretics has not been included due to 
a broad confidence interval.   
†Trial result comparing ARB+Neprilysin inhibitor to ACE inhibitor. 
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Table 1. Effects of systolic heart failure treatments included in the BANDAID2 mnemonic on total mortality and hospitalisation rates. 
 Drug Comparison Trial type  End points HR/RR/OR ARR for Mortality 
Beta-blockers Placebo 7 Meta-
analysis 
Total mortality 
(22 RCTs, n=10,135) 
OR 0.65, 95% CI [0.53-0.80]  4.4% at 1 year 
   Hospitalisation for HF 
(22 RCTs, n= 10,076) 
OR 0.64, 95% CI [0.53-0.79]  
ACEI Placebo 12 Meta-
analysis 
Total mortality 
(32 RCTs, n=7105) 
OR 0.77, 95% CI [0.67-0.88], P<0.001 ≤3 months: 5.4% 
3 months to 4 years: 
5.8% 
   Total mortality or hospitalisation for HF  
(30 RCTs, n=6988) 
OR 0.65, 95% CI [0.57-0.74], P<0.001  
ARB Placebo 17 Meta-
analysis  
Total mortality 
(9 RCTs, n=4643) 
RR 0.87, 95% CI [0.76-1.00], P=0.05 7.1% at 1.3 years 
   Hospitalisation for HF 
(3 RCTs, n=2590) 
RR 0.71, 95% CI [0.61-0.82] 
P<0.00001 
 
 ACEI 17 Meta-
analysis 
Total mortality 
(8 RCTs, n=5201) 
RR 1.05, 95% CI [0.91-1.22], P=0.48 NA 
   Hospitalisation for HF 
(3 RCTs, n=4310) 
RR 0.96, 95% CI [0.83-1.11], P=0.58 
 
 
ARB+ACEI ACEI 17  Total mortality 
(7 RCTs, n=8260) 
RR 0.98, 95% CI [0.90-1.06], P=0.60 NA 
   Hospitalisation for HF 
(4 RCTs, n=8108) 
RR 0.81, 95% CI [0.74-0.89],  
P<0.00001 
 
H-ISDN Placebo 20 RCT Total mortality 
(n=642) 
RR 0.66, 95% CI [0.46-0.96], P<0.028 5.3% at 2 years 
 ACEI 21 RCT Total mortality 
(n=804) 
RR 1.39 (CI not stated), P=0.016  -5.4% at 2 years 
LCZ696 (ARB + 
Neprilysin inhibitor) 
ACEI 42 RCT,  Total mortality 
(n=10521) 
HR 0.84, 95% CI [0.76-0.93], P<0.001 4.7% at 2.3 years 
   Hospitalisation for HF 
(n=10521) 
HR 0.79, 95% CI [0.71-0.89], P<0.001  
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Diuretics Placebo 23 Meta-
analysis 
Total mortality 
(3 studies (1 RCT), n=202) 
OR 0.24, 95% CI  [0.07-0.83], P=0.02 8% at ~6months 
   Hospitalisation for HF 
2 withdrawal studies, n=169 
OR 0.07, 95% CI [0.01-0.52], P=0.01  
Aldosterone 
antagonist 
Placebo  Meta-
analysis 
Total mortality 24 
(7 RCTs, n=11,826) 
OR 0.74, 95% CI [0.63-0.86], P<0.001 10.4% at 2.2 years 
  Meta-
analysis 
All-cause hospitalisation 25 
(7 RCTs, n=8699) 
RR 0.73, 95% CI [0.63-0.84], 
P<0.0001 
 
Ivabradine Placebo 26 Meta-
analysis  
Total mortality 
(2 RCTs, n=7632) 
HR 0.96, 95% CI 0.87-1.05, p=NS 
(Overall population) 
 
HR 0.89, 95% CI [0.80-1.00], P=0.048 
(HR≥75bpm subgroup) 
NA 
 
 
2% at 1.8 years 
   Hospitalisation for HF 
(2 RCTs, n=7632) 
HR 0.78, 95% CI [0.70-0.87] P<0.0001  
AICD Medical 
therapy 27 
Meta-
analysis 
Total mortality 
(7 RCTs, n=4981) 
RR 0.74, 95% CI [0.67-0.83], 
P<0.00001 
6.5% at 2 years  
 
CRT AICD or 
medical 
therapy 29 
Meta-
analysis 
Total mortality 
(5 RCTs,  n=3872) 
HR 0.66, 95% CI [0.57-0.77] 2.9% at 1 year 
   Total mortality or hospitalisation for HF 
(5 RCTs,  n=3872) 
HR 0.65, 95% CI [0.58–0.74]  
Digoxin Placebo 33 Meta-
analysis 
Total mortality 
(8 RCTs, n=7755) 
OR 0.98, 95% CI [0.89-1.09], P=0.76 NA at 3 years 
   Hospitalisation for HF 
(4 RCTs, n=7262) 
OR 0.68, 95% CI [0.61-0.75], 
P<0.00001 
 
   Improved clinical status 
12 studies, n=1234  
OR 0.31, 95% CI [0.21-0.43], 
P<0.00001 
 
HR=hazard ratio; RR=risk ratio; OR=odds ratio. These methods give similar estimates when event rates are relatively low. 
ARR=absolute risk reduction.  
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Table 2. Indications, contraindications and major society recommendations for systolic heart failure treatments. 
Treatment Indications Level of Evidence Class/Grade of 
Recommendation 
Contraindications 
Relative Absolute 
Beta-blocker  NYHA II-IV 
 EF ≤40% 
ESC: A 
ACCF/AHA: A 
 
ESC: I 
ACCF/AHA: I 
NHF: A 
 Conduction disease 
 Symptomatic hypotension or 
bradycardia 
 Reversible airways disease  
 Hypersensitivity 
 Decompensated 
heart failure 
ACE 
inhibitor/ARB 
 NYHA I-IV 
 EF ≤40% 
ESC: A 
ACCF/AHA: A 
 
ESC: I 
ACCF/AHA: I 
NHF: A 
 Renal dysfunction 
 Hypotension 
 Hypersensitivity 
 Pregnancy 
Nitrate-
Hydralazine 
 Alternative to 
ACEI/ARB 
(General 
population) 
OR 
 Addition to 
ACEI (African 
Americans) 
 NYHA III-IV 
 EF ≤35% 
ESC: B 
ACCF/AHA: B 
 
 
(ACCF/AHA: A for 
African Americans) 
 
ESC: IIb 
ACCF/AHA: IIa 
NHF: B 
 
(ACCF/AHA: I for 
African Americans) 
 Hypotension 
 Intolerable headache 
 Hypersensitivity 
 
Diuretics  Volume 
overload 
ESC: N/A 
ACCF/AHA: C 
 
ESC: I 
ACCF/AHA: I 
NHF: D 
 Hyponatraemia 
 Hypokalemia 
 Hypotension 
 Hypersensitivity 
 
Aldosterone 
antagonist 
 NYHA II-IV 
 EF ≤35% 
ESC: A 
ACCF/AHA: A 
 
ESC: I 
ACCF/AHA: I 
NHF: B 
 Hyperkalemia (>5.0 mmol/L) 
 Stage 1-2 CKD 
 
 Hypersensitivity 
 Stage 3+ CKD  
Ivabradinei  NYHA II-IV 
 EF ≤35% 
 Sinus rhythm 
 HR ≥70bpm 
 Maximum 
ESC: B 
ACCF/AHA: N/A 
ESC: IIa 
ACCF/AHA: N/A 
NHF: B 
 Hypotension 
 Moderate-severe hepatic 
failure 
 End stage renal failure 
 Combination with 
 Hypersensitivity 
 Sick sinus syndrome 
 AV or SA block 
 HR<50  
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tolerable BB 
dose 
 
cytochrome P450 3A4 
inhibitors 
 
Devices  AICD  NYHA II-III 
 EF ≤35% 
 Sinus rhythm 
 Medical 
therapy ≥3 
months 
 Prognosis ≥1 
year 
ESC: Aii 
ACCF/AHA: A 
 
ESC: I 
ACCF/AHA: I 
NHF: A 
 Incessant VT/VF 
 Severe psychiatric conditions 
 Poor prognosis  
 Extensive lateral LV wall 
scarring (CRT) 
 Uncontrolled 
systemic infection 
 Unsuitable vascular 
anatomy 
 
CRT  QRS ≥120ms 
 Refer to 
specific criteria 
for each NYHA 
class in 
guidelines 
ESC: A 
ACCF/AHA: A 
 
ESC: I 
ACCF/AHA: I 
NHF: A 
Digoxin  Last line 
therapy for 
symptomatic 
relief 
 
ESC: B 
ACCF/AHA: B 
 
ESC: IIb 
ACCF/AHA: IIa 
NHF:B 
 Renal dysfunction  Hypersensitivity 
 
i Ivabradine is recommended for HR ≥70bpm in Australian National Heart Foundation Guidelines (2011) but PBS subsidies are only provided for HR≥77bpm. 
ii Level B for non-ischaemic causes of heart failure 
iii Level of evidence and class of recommendation varies according to criteria 
iv Class IIa for non-LBBB QRS morphology 
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Figure 1. PRISMA flow diagram for search strategy results. 
Records identified through 
database searching 
(n = 2656) 
Additional records identified 
through other sources 
(n = 6) 
Screened for duplicates 
(n = 2662) 
Title and abstract 
screened  
(n=2527) 
 
Records excluded 
(n = 1918) 
Full-text articles reviewed 
(n = 609) 
 
Treatment studies 
referenced   
(n=36) 
Records excluded 
(n=135) 
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Figure 2. Effects on total mortality in patients with systolic heart failure, by treatment allocation 
compared to placebo.  
 
OR=odd ratio; HR=hazard ratio; RR=risk ratio 
*Combination pharmacotherapy represents a broad estimate of the potential clinical benefits from 
combining treatments marked with an asterisk. The effect of diuretics has not been included due to 
a broad confidence interval.   
†Trial result comparing ARB+Neprilysin inhibitor to ACE inhibitor. 
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Supplementary Appendix 
Search strategy 
Keyword searches were performed in Medline and Embase as described below, for the following 
treatments:  
“angiotensin-converting enzyme inhibitors”, “angiotensin receptor antagonists”, “adrenergic beta-
antagonists” (Medline) or “beta adrenergic receptor blocking agent” (Embase), diuretics (Medline) 
or “diuretic agent” (Embase), “mineralocorticoid receptor antagonists” (Medline) or “aldosterone 
antagonist” (Embase), “ivabradine”, “defibrillators, implantable” (Medline) or “'implantable 
cardioverter defibrillator” (Embase), “cardiac resynchronization therapy”, “digoxin”, [“isosorbide 
dinitrate” or “hydralazine”], “fatty acids, omega-3” (Medline) or “omega 3 fatty acid” (Embase), 
[“Anticoagulants” or “Warfarin” or “Platelet Aggregation Inhibitors” or “Aspirin” or “Purinergic P2Y 
Receptor Antagonists”] (Medline) or [“anticoagulant agent” or “antithrombocytic agent”] (Embase), 
“hydroxymethylglutaryl-CoA reductase inhibitors” (Medline) or “'hydroxymethylglutaryl coenzyme a 
reductase inhibitor” (Embase), “neprilysin inhibitor” (Medline) or “enkephalinase inhibitor” 
(Embase) 
MEDLINE: 
1. “meta-analysis or systematic review or randomised controlled trial or randomized controlled 
trial”[Publication Type], 2. “(heart failure or ventricular dysfunction)”[Subject Heading], 3. 1 & 2, 4. 
Limit 3 to “core clinical journals (aim)” and “English language”, 5. “(drug name)”[Subject Heading], 6. 
4 & 5.  
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EMBASE: 
1.'heart failure'/mj OR 'ventricular dysfunction'/mj AND ([cochrane review]/lim OR [systematic 
review]/lim OR [controlled clinical trial]/lim OR [randomized controlled trial]/lim OR [meta 
analysis]/lim) AND [humans]/lim AND [english]/lim 2.'drug name'/mj 3.1 & 2. 
 
 
 
 
 
